Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (192) 192
Publication (57) 57
Book Review (38) 38
Conference Proceeding (5) 5
Book / eBook (2) 2
Book Chapter (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (128) 128
humans (122) 122
melanoma (94) 94
oncology (68) 68
article (55) 55
braf (54) 54
melanoma - pathology (53) 53
cancer (52) 52
animals (48) 48
melanoma - drug therapy (47) 47
melanoma - genetics (41) 41
cell line, tumor (39) 39
melanoma - metabolism (39) 39
proto-oncogene proteins b-raf - antagonists & inhibitors (35) 35
proto-oncogene proteins b-raf - genetics (34) 34
cell biology (31) 31
malignant-melanoma (28) 28
neoplasms (27) 27
resistance (26) 26
dermatology (25) 25
mice (25) 25
mutation (24) 24
metastatic melanoma (22) 22
mutations (22) 22
protein kinase inhibitors - pharmacology (22) 22
therapy (22) 22
pharmacology & pharmacy (21) 21
proto-oncogene proteins b-raf - metabolism (21) 21
skin neoplasms - pathology (19) 19
antineoplastic agents - therapeutic use (18) 18
care and treatment (17) 17
b-raf (16) 16
molecular targeted therapy (16) 16
skin neoplasms - genetics (16) 16
female (15) 15
melanoma - enzymology (15) 15
signal transduction (15) 15
skin neoplasms - drug therapy (15) 15
mek inhibition (14) 14
research (14) 14
vemurafenib (14) 14
acquired-resistance (13) 13
apoptosis (13) 13
drug resistance, neoplasm (13) 13
male (13) 13
metastasis (13) 13
nras (13) 13
protein kinase inhibitors - therapeutic use (13) 13
signal transduction - drug effects (13) 13
targeted therapy (13) 13
growth (12) 12
melanoma - therapy (12) 12
membrane proteins - genetics (12) 12
open-label (12) 12
proteins (12) 12
survival (12) 12
tumors (12) 12
apoptosis - drug effects (11) 11
cells (11) 11
expression (11) 11
health aspects (11) 11
immunotherapy (11) 11
pathway (11) 11
phosphorylation (11) 11
prognosis (11) 11
skin neoplasms - metabolism (11) 11
antineoplastic agents - pharmacology (10) 10
biochemistry & molecular biology (10) 10
disease progression (10) 10
erk (10) 10
genetic aspects (10) 10
improved survival (10) 10
in-vitro (10) 10
neoplasms - drug therapy (10) 10
up-regulation (10) 10
braf mutations (9) 9
drug resistance (9) 9
drug-resistance (9) 9
gene mutations (9) 9
gtp phosphohydrolases - genetics (9) 9
models, biological (9) 9
proteomics (9) 9
signaling (9) 9
xenograft model antitumor assays (9) 9
breast-cancer (8) 8
cell proliferation - drug effects (8) 8
cell-lines (8) 8
cutaneous melanoma (8) 8
drug resistance, neoplasm - genetics (8) 8
enzyme inhibitors - pharmacology (8) 8
indoles - pharmacology (8) 8
map kinase (8) 8
melanoma-cells (8) 8
mutant melanoma (8) 8
phosphatidylinositol 3-kinases - metabolism (8) 8
progression (8) 8
signaling pathways (8) 8
abridged index medicus (7) 7
activated protein-kinase (7) 7
activation (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Current chalenges in personalized cancer medicine
by Smalley, Keiran S. M
2012, First edition., Advances in pharmacology ( San Diego, Calif.), ISBN 0123979277, Volume 65
Treatment | genetics | methods | therapy | Pharmacology | Targeted Gene Repair | Individualized Medicine | Molecular Targeted Therapy | Neoplasms | Cancer
Web Resource
Details down arrow
2. Full Text Pharmacological research and cancer: A call to arms
by Smalley, Keiran S.M
Pharmacological Research, ISSN 1043-6618, 08/2019, Volume 146, pp. 104291 - 104291
PHARMACOLOGY & PHARMACY | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
by Smalley, Keiran S.M
Journal of Investigative Dermatology, ISSN 0022-202X, 01/2010, Volume 130, Issue 1, pp. 28 - 37
Despite years of research, there has been little improvement in survival for patients with disseminated melanoma. Recent work has identified mutations in and ,... 
METASTATIC MELANOMA | PHASE-II TRIAL | BRAF MUTATIONS | ORAL MEK INHIBITOR | INHIBITOR AZD6244 ARRY-142886 | MALIGNANT-MELANOMA | B-RAF | CELL-LINES | PROTEIN-KINASE ACTIVATION | IMATINIB MESYLATE | DERMATOLOGY | Melanoma - metabolism | Skin Neoplasms - drug therapy | Signal Transduction - drug effects | Humans | Melanoma - drug therapy | Signal Transduction - physiology | Enzyme Inhibitors - therapeutic use | Skin Neoplasms - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Increased immunity and BRAF inhibition: Yet another argument for combination therapy?
by Smalley, Keiran S.M
Pharmacological Research, ISSN 1043-6618, 11/2016, Volume 113, Issue Pt A, pp. 719 - 720
UNTREATED MELANOMA | TUMOR | PHARMACOLOGY & PHARMACY | NIVOLUMAB | EXPRESSION | IPILIMUMAB | VEMURAFENIB | Immunotherapy - methods | Humans | Indoles - administration & dosage | Enzyme Inhibitors - administration & dosage | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Immunity, Cellular - immunology | Protein Kinase Inhibitors - administration & dosage | Animals | Immunity, Cellular - drug effects | Immunotherapy - trends | Drug Therapy, Combination | Proto-Oncogene Proteins B-raf - metabolism | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases
by Smalley, Keiran S.M and Forsyth, Peter A
Pharmacological Research, ISSN 1043-6618, 09/2018, Volume 135, pp. 265 - 267
DABRAFENIB | SURVIVAL | TRIAL | IMPACT | THERAPY | RESISTANCE | PHARMACOLOGY & PHARMACY | MECHANISMS | VEMURAFENIB | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Making melanoma therapy personal: an interview with Dr Keiran Smalley for
by Smalley, Keiran SM
Melanoma Management, ISSN 2045-0885, 05/2017, Volume 4, Issue 2, pp. 95 - 97
Dr Smalley earned his PhD in Pharmacology from the University of Cambridge, UK, in 2001. He worked as a post-doctoral fellow in the Oncology Department of... 
targeted therapy | immunotherapy | melanoma | BRAF
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text ERK inhibition: A new front in the war against mapk pathway-driven cancers?
by Smalley, Inna and Smalley, Keiran S. M
Cancer Discovery, ISSN 2159-8274, 02/2018, Volume 8, Issue 2, pp. 140 - 142
ERK inhibitors have enormous therapeutic potential against tumors that are BRAF mutant, BRAF-MEK inhibitor resistant, or RAS mutant. In this issue of Cancer... 
RESISTANCE | BRAF | MELANOMA | EVOLUTION | ONCOLOGY | Aminopyridines | Protein Kinase Inhibitors | Proto-Oncogene Proteins B-raf - genetics | Humans | Pyrroles | Cell Line, Tumor | Mutation | MAP Kinase Signaling System | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity
by James Tsai and John T. Lee and Weiru Wang and Jiazhong Zhang and Hanna Cho and Shumeye Mamo and Ryan Bremer and Sam Gillette and Jun Kong and Nikolas K. Haass and Katrin Sproesser and Ling Li and Keiran S. M. Smalley and Daniel Fong and Yong-Liang Zhu and Adhirai Marimuthu and Hoa Nguyen and Billy Lam and Jennifer Liu and Ivana Cheung and Julie Rice and Yoshihisa Suzuki and Catherine Luu and Calvin Settachatgul and Rafe Shellooe and John Cantwell and Sung-Hou Kim and Joseph Schlessinger and Kam Y. J. Zhang and Brian L. West and Ben Powell and Gaston Habets and Chao Zhang and Prabha N. Ibrahim and Peter Hirth and Dean R. Artis and Meenhard Herlyn and Gideon Bollag
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2008, Volume 105, Issue 8, pp. 3041 - 3046
$BRAF^{V600E}$ is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targeting "active" protein kinases have demonstrated... 
Phosphorylation | Sulfonamides | Medical treatment | Melanoma | Cell lines | Cell cycle | Genetic mutation | Heterologous transplantation | Tumors | Cancer | Protein kinases | Cell signaling | ACTIVATION | MULTIDISCIPLINARY SCIENCES | protein kinases | melanoma | TYROSINE KINASES | BRAF | PATHWAY | cell signaling | RESISTANCE | cancer | SENESCENCE | MUTATIONS | phosphorylation | PROGRESSION | SCAFFOLD | Oncogenes - genetics | Sulfonamides - chemistry | Apoptosis - drug effects | Escherichia coli | Humans | Models, Molecular | Mice, SCID | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - chemistry | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Inhibitory Concentration 50 | Indoles - therapeutic use | Mice | Molecular Structure | Phosphorylation - drug effects | Cell Cycle - drug effects | Indoles - chemistry | Control | Care and treatment | Enzyme inhibitors | Influence | Cellular signal transduction | Research | Properties | Mutation (Biology) | Models | Mutation | Kinases | Apoptosis | Index Medicus | Biological Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Get with the Program! Stemness and Reprogramming in Melanoma Metastasis
by Faião-Flores, Fernanda and Smalley, Keiran S.M
Journal of Investigative Dermatology, ISSN 0022-202X, 01/2018, Volume 138, Issue 1, pp. 10 - 13
Cancer cells are highly plastic and adopt multiple phenotypic states that contribute to tumor progression. Heppt et al. demonstrate that the homeodomain... 
DRIVES | THERAPY | DERMATOLOGY | Melanoma - genetics | Humans | Gene Expression Regulation, Neoplastic | Transcription Factors | MSX1 Transcription Factor | Disease Progression | Neural Crest | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy
by Smalley, Keiran S.M and Sondak, Vernon K
The New England Journal of Medicine, ISSN 0028-4793, 08/2010, Volume 363, Issue 9, pp. 876 - 878
Personalized medicine has long been a mainstay of the treatment of localized melanoma, involving surgical decisions that are individualized on the basis of... 
CELLS | MEDICINE, GENERAL & INTERNAL | BRAF | RAF | STAGE | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Sulfonamides - therapeutic use | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Humans | Melanoma - drug therapy | Indoles - therapeutic use | Mutation | Drug Resistance | Proteins | Chemotherapy | Kinases | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
by Yin, Qing and Han, Tao and Fang, Bin and Zhang, Guolin and Zhang, Chao and Roberts, Evan R and Izumi, Victoria and Zheng, Mengmeng and Jiang, Shulong and Yin, Xiu and Kim, Minjung and Cai, Jianfeng and Haura, Eric B and Koomen, John M and Smalley, Keiran S. M and Wan, Lixin
Nature Communications, ISSN 2041-1723, 12/2019, Volume 10, Issue 1, pp. 1870 - 1870
BRAF plays an indispensable role in activating the MEK/ERK pathway to drive tumorigenesis. Receptor tyrosine kinase and RAS-mediated BRAF activation have been... 
LIGASE ITCH | REGULATOR | ACTIVATION | ITCH/AIP4 | MACROPHAGES | MULTIDISCIPLINARY SCIENCES | RESISTANCE | DEGRADATION | PROTEINS | TNF | PROGRESSION | Skin Neoplasms - pathology | Phosphorylation | Cytokines - metabolism | Cell Survival | Humans | Ubiquitin-Protein Ligases - metabolism | JNK Mitogen-Activated Protein Kinases - metabolism | Male | Melanoma - pathology | MAP Kinase Signaling System | 14-3-3 Proteins - metabolism | Xenograft Model Antitumor Assays | Ubiquitination | Animals | Cell Transformation, Neoplastic | Mice, Nude | HEK293 Cells | Inflammation Mediators - metabolism | Cell Line, Tumor | Lysine - metabolism | Mice | Proto-Oncogene Proteins B-raf - metabolism | Repressor Proteins - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text SinCHet: A MATLAB toolbox for single cell heterogeneity analysis in cancer
by Li, Jiannong and Smalley, Inna and Schell, Michael J and Smalley, Keiran S. M and Ann Chen, Y
Bioinformatics, ISSN 1367-4803, 2017, Volume 33, Issue 18, pp. 2951 - 2953
aSummary: Single-cell technologies allow characterization of transcriptomes and epigenomes for individual cells under different conditions and provide... 
VISUALIZATION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | BIOCHEMICAL RESEARCH METHODS | MATHEMATICAL & COMPUTATIONAL BIOLOGY | Index Medicus | Applications Notes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression
by Paraiso, Kim H. T and Xiang, Yun and Rebecca, Vito W and Abel, Ethan V and Chen, Y. Ann and Munko, A. Cecilia and Wood, Elizabeth and Fedorenko, Inna V and Sondak, Vernon K and Anderson, Alexander R. A and Ribas, Antoni and Palma, Maurizia Dalla and Nathanson, Katherine L and Koomen, John M and Messina, Jane L and Smalley, Keiran S. M
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 7, pp. 2750 - 2760
This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor PLX4720. Immunohistochemical staining of a tissue array covering all... 
METASTATIC MELANOMA | APOPTOSIS | PROTEIN | ONCOLOGY | PHOSPHORYLATION | CUTANEOUS MELANOMA | RAF KINASE | CANCER | MEDIATES RESISTANCE | LINES | ERK | RNA, Small Interfering - genetics | Up-Regulation | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins - biosynthesis | Bcl-2-Like Protein 11 | Melanoma - genetics | Apoptosis Regulatory Proteins - genetics | Indoles - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins B-raf - metabolism | Apoptosis Regulatory Proteins - biosynthesis | Melanoma - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | PTEN Phosphohydrolase - deficiency | Membrane Proteins - genetics | PTEN Phosphohydrolase - biosynthesis | Proto-Oncogene Proteins - genetics | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Membrane Proteins - biosynthesis | Membrane Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Apoptosis Regulatory Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Mutation | RNA, Small Interfering - administration & dosage | Index Medicus | PTEN | melanoma | BRAF | PLX4032 | therapy | resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Why do women with melanoma do better than men?
by Smalley, Keiran S. M
eLife, ISSN 2050-084X, 01/2018, Volume 7
Harnessing female sex hormones may improve how all patients with melanoma respond to treatment. 
Female | Male | Humans | Melanoma | Skin Neoplasms | Women | Prognosis | Ipilimumab | Hormones, Sex | Skin | Risk factors | Skin cancer | Transcription factors | Research | Hormones | Cancer therapies | Proteins | Sex hormones | Medical prognosis | Immunotherapy | Females | Immune system | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The complexity of microenvironment-mediated drug resistance
by Fedorenko, Inna V and Smalley, Keiran S. M
Genes and Cancer, ISSN 1947-6019, 2015, Volume 6, Issue 9-10, pp. 367 - 368
Fibroblasts | Host | Microenvironment | Drug resistance | Melanoma | microenvironment | host | melanoma | fibroblasts | drug resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression
by Liu, Zhao-Jun and Xiao, Min and Balint, Klara and Smalley, Keiran S. M and Brafford, Patricia and Qiu, Ruihua and Pinnix, Chelsea C and Li, Xueli and Herlyn, Meenhard
Cancer Research, ISSN 0008-5472, 04/2006, Volume 66, Issue 8, pp. 4182 - 4190
Cellular signaling mediated by Notch receptors results in coordinated regulation of cell growth, survival, and differentiation. Aberrant Notch activation has... 
TRANSFORMATION | SYSTEM | ADHESION | CANCER CELLS | GENE | ONCOLOGY | ENDOTHELIAL-CELLS | TUMOR-SUPPRESSOR | GROWTH-FACTOR | DIFFERENTIATION | MUTATIONS | Up-Regulation | MAP Kinase Signaling System - physiology | Antigens, CD - biosynthesis | Humans | Melanoma - enzymology | Cell Growth Processes - physiology | Phosphatidylinositol 3-Kinases - metabolism | Antigens, CD - genetics | Cadherins - biosynthesis | DNA-Binding Proteins - metabolism | Cadherins - genetics | Proto-Oncogene Proteins c-akt - metabolism | Spheroids, Cellular | Trans-Activators | Nuclear Proteins - metabolism | Melanoma - pathology | Receptor, Notch1 - metabolism | Mice, SCID | Disease Progression | Receptor, Notch1 - biosynthesis | Animals | Cell Adhesion - physiology | Cell Line, Tumor | Mice | Transcription Factors | Enzyme Activation | Receptor, Notch1 - genetics | Mitogen-Activated Protein Kinases - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
by Keiran S.M. Smalley and Nikolas K. Haass and Patricia A. Brafford and Mercedes Lioni and Keith T. Flaherty and Meenhard Herlyn
Molecular Cancer Therapeutics, ISSN 1535-7163, 05/2006, Volume 5, Issue 5, pp. 1136 - 1144
Although >66% of melanomas harbor activating mutations in BRAF and exhibit constitutive activity in the mitogen-activated protein kinase/extracellular... 
microenvironment | melanoma | MAPK | chemotherapy | phosphatidylinositol 3-kinase | B-V599E-RAF | ONCOLOGY | IN-VIVO | GROWTH | ORAL MEK INHIBITOR | ONCOGENIC MUTATIONS | MALIGNANT-MELANOMA | B-RAF | G1 PHASE | EXPRESSION | CANCER | Melanoma - metabolism | Nitriles - metabolism | Butadienes - pharmacology | Enzyme Inhibitors - metabolism | Nitriles - pharmacology | Humans | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Morpholines - metabolism | MAP Kinase Kinase Kinases - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Melanoma - pathology | Enzyme Activation - drug effects | Protein Subunits - metabolism | Neoplasm Metastasis | Signal Transduction - drug effects | Butadienes - metabolism | Cell Line, Tumor | Chromones - metabolism | Chromones - pharmacology | Spheroids, Cellular | Drug Resistance, Neoplasm - physiology | Protein Subunits - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Ipilimumab
by Kudchadkar, Ragini and Sondak, Vernon K and Grippon, Seden and Smalley, Keiran S. M and Kirkpatrick, Peter
Nature Reviews Drug Discovery, ISSN 1474-1776, 06/2011, Volume 10, Issue 6, pp. 411 - 412
  In March 2011, ipilimumab (Yervoy; Bristol-Myers Squibb), a human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4 (CTLA4),... 
METASTATIC MELANOMA | PHARMACOLOGY & PHARMACY | INHIBITION | BLOCKADE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CTLA-4 Antigen | Antigens, CD - immunology | Animals | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Humans | Ipilimumab | Melanoma - drug therapy | Antibodies, Monoclonal - therapeutic use | Melanoma - secondary | Product development | Pharmaceutical industry | Licensing, certification and accreditation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape
by Fedorenko, Inna V and Wargo, Jennifer A and Flaherty, Keith T and Messina, Jane L and Smalley, Keiran S.M
Journal of Investigative Dermatology, ISSN 0022-202X, 12/2015, Volume 135, Issue 12, pp. 3115 - 3124
The current study defines a fibroblast-derived niche that facilitates the therapeutic escape of melanoma cells from BRAF inhibition. Vemurafenib treatment led... 
SURVIVAL | BINDING DOMAINS | CELLS | RESISTANCE CAM-DR | MELANOMA | GROWTH | FIBRONECTIN | RAF INHIBITORS | STROMAL FIBROBLASTS | FOCAL ADHESION KINASE | DERMATOLOGY | Fibronectins - analysis | Humans | Proto-Oncogene Proteins c-akt - physiology | Melanoma - pathology | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Transforming Growth Factor beta - pharmacology | Sulfonamides - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Phosphatidylinositol 3-Kinases - physiology | Indoles - therapeutic use | Protein Kinase Inhibitors - pharmacology | Index Medicus | melanoma | fibroblasts | BRAF | resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights